
AstraZeneca Plans $1.5B Manufacturing Site for Global Production of ADC Cancer Drugs
The Singapore manufacturing site will be AstraZeneca’s first facility capable of handling all steps of antibody drug conjugate production. AstraZeneca aims to open the facility in 2029.